Insulin glargine and lixisenatide study results released
A combination of insulin glargine and lixisenatide helps people with type 2 diabetes reach meal-time blood sugar targets better, according to a new study.
The LixiLan-L trial investigated a fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide (iGlarLixi) in adults with type 2 diabetes.
The findings, unveiled by Sanofi at the European Association for the Study of Diabetes 52nd Annual Meeting in Munich, showed those who took the fixed-ratio combination demonstrated greater post meal glycaemic control compared with insulin glargine alone.
Dr Mike Baxter, medical therapy expert at Sanofi UK, said: “Blood glucose management in the UK is amongst the worst in Europe with, on average, people with type 2 diabetes having the highest blood glucose levels compared to nine other developed countries.
“These latest studies reflect Sanofi’s ongoing commitment to innovative approaches in developing medicines that are intended to help patients manage their condition and reduce the risk of avoidable complications.”
A total of 736 people with type 2 diabetes, who were not adequately controlled at screening on basal insulin, alone or combined with one to two oral anti-diabetic agents, took part in the 30 week trial.
Treatment with metformin, if previously taken, was continued throughout the study while other oral agents were discontinued.
Post hoc analyses were performed to assess the percentage of patients reaching PPG
P-values were calculated between treatment groups for all parameters analysed. At Week 30, the percentage of patients with PPG
Compared with iGlar, treatment with iGlarLixi also resulted in a significantly greater reduction in PPG AUC02h. SMPG profiles at time points after three daily meals showed larger percentages of iGlarLixi patients at the PPG targets compared with iGlar, with the difference decreasing postdinner.